America's COVID treatment arsenal is still dangerously understocked, experts warn, and more government funding may be required to bring new drugs to market quickly enough.
Between the lines: Having one reliable antiviral and one effective monoclonal antibody is far from ideal heading into the fall, but the federal government says it doesn't have enough money to buy more of the existing therapeutics, let alone invest in new ones.
